Pathological activation of MR leads to an increased risk for cardiovascular (CV) events [7, 8] and MR blockade using the marketed MR antagonists (MRA) spironolactone and eplerenone has proven to be an effective therapy for treatment of heart failure and hypertension [9–11]. Here, NR3C2 is linked to hypertensive disorder.